Mikhail Blagosklony is a researcher and professor of Oncology at the Rosewell Park Cancer Institute in Buffalo, New York. He is specifically interested in the field of medical research and has focused particularly on the link between cancer and aging. In his capacity as Editor-in-Chief of Oncotarget, Mikhail has carried-out and published extensive research on the subject of aging. His contribution to this specific field of science is immense and unparalleled, with the interesting topics he picks regarding cancer and aging attracting much attention within the medical field.Mikhail’s goal has been to figure out ways in which elimination of cancerous cells can be possible without the destruction of normal cells that are particularly crucial to the recovery of both the body and mind after long periods of cancer treatment. Mikhail has undoubtedly been a great inspiration to his peers and students who wish to continue expanding on his research in future.Besides researching on the efficient ways of treating cancer, Mikhail has also been focusing on finding ways in which this dangerous and tragic can be treated in a cost-effective manner. He believes that in future, cancer treatment will no longer be a luxury treatment for those who are financially stable, but rather will be an easy and cost-effective treatment.
Mikhail’s Research on Rapamycin
Mikhail is widely-known for advocating the use of a cancer drug known as Rapamycin, also commonly referred to as Sirolimus or Rapamune in the pharmacy market. Rapamycin was initially used as an anti-fungal agent, but was later used in other ways after it was discovered that it possessed remarkable antiproliferative and immunosuppressive properties.There are various reasons as to why Rapamycin is regarded as one of the best medicines ever discovered. Firstly, it has antiproliferative properties that make it efficient in reducing the risk of cancer in patients with organ transplants. Secondly, it has immunosuppressive properties that are vital to patients with organ transplants. Compared to other anti-rejection drugs, Rapamycin displays minimum toxicity levels towards kidneys. Rapamycin has also been found to be best for treating patients with hemolytic-uremic syndrome as it contains low levels of toxicity towards kidneys.
Another reason why Rapamycin is a wonder drug is because it is efficient in treating Lymphangioleiomyomatosis (LAM), an extremely rare disease that affects women of child-bearing age.Rapamycin is the primary drug approved for the treatment of this disease as it helps to block the release of lymphangiogenic growth factors. In addition, Rapamycin has been found to be efficient in treating other health conditions such as Tuberous Sclerosis Complex, Facial Angiofibromas, as well as the prevention of re-stenosis. Multiple researches are in progress to establish Rapamycin’s potential in treating conditions such as Alzheimer’s disease, Muscular Dystrophy, and Systemic Lupus Erythematosus. Mikhail Blagosklonny has played a huge role in pioneering the utilization of Rapamycin to treat a variety of aliments, as well as advocating the use of the drug to prolong human life. While research is still ongoing in certain treatment procedures, the initial results are encouraging enough to keep hopes alive.